Compare ACADIA Pharmaceuticals Inc. (ACAD) vs TeraWulf Inc (WULF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs TeraWulf Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while TeraWulf Inc trades at $21.64 (market cap $10.04B). The key difference: TeraWulf Inc is far larger — about 2.2× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | WULF | |
|---|---|---|
Market Cap | $4.49B | $10.04B |
Sector | Health | Technology |
52-Week High | $28.06 | $28.98 |
52-Week Low | $20.06 | $4.76 |
Enterprise Value | $3.69B | $12.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
WULF trades at $22.21, up 4.86% with strong analyst support despite bearish technical signals. The company recently secured a transformative $19 billion AI infrastructure deal with Anthropic, shifting focus from Bitcoin mining to long-term contracted revenue. However, fundamentals show significant challenges with negative profit margins (-611.46%) and high valuation ratios (P/S 53.86, P/B 84.25) amid consecutive earnings misses.
The outlook balances substantial AI opportunity against current financial weakness. The 20-year Anthropic contract provides revenue visibility, but execution risks and negative cash flow from operations (-$123M) require careful monitoring. With 100% analyst buy ratings and $32.40 consensus target offering 46% upside, the stock presents high-risk, high-reward potential for investors believing in the AI infrastructure pivot.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
